MRNA for treating metabolic diseases, pharmaceutical composition and application
Patent Information
- Application Number
- CN202510173644.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-18
- Publication Date
- 2025-07-04
AI Technical Summary
The existing drugs for treating hyperuricemia and gout are difficult to balance the effectiveness and side effects. Traditional drugs such as allopurinol and uridase drugs have problems such as large side effects and poor treatment effects during use.
An mRNA containing a specific CDS coding region was designed and prepared into a liposome nanoparticle delivery system by optimizing the nucleotide sequence and modifying it, which is used to express uricase in the body and reduce uric acid levels in the blood.
It significantly reduces TNFα and IL-8 levels in the body, reduces inflammatory response, improves the effect of reducing uric acid, prolongs the half-life, improves bioavailability, and reduces side effects. It is suitable for a variety of patient groups.
Smart Images

Figure CN120242072A_ABST